| |
|
|
|
|
|
 |
| |
|
¾Ú¾Á¸°ÁÖ500mg AMCILLIN VIAL.[Ampicillin sodium]
|
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
643305280[A01202771]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1B(2000.02.29)(ÇöÀç¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»öÀÇ ¹«Ãë °í¹ÌÀÇ °áÁ¤¼º ºÐ¸» ÁÖ»çÁ¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
1VIAL |
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
¡Û À¯È¿±ÕÁ¾
½ºÆ®·¾ÅäÄÛÄí½º ÇÇ¿À°Ô³×½º(±×·ìA-º£Å¸¿ëÇ÷¼º), Æó·Å¿¬¼â±¸±Õ, ÇÁ·ÎÅ׿콺(ƯÈ÷, ÇÁ·ÎÅ׿콺 ¹Ì¶óºô¸®½º), ÀÎÇ÷翣ÀÚ±Õ, ÀåÆ¼Çª½º±Õ, Àå³»±¸±Õ, ½Ã°Ö¶ó, ´ëÀå±Õ, Æ÷µµ±¸±Õ, ÀÓ±Õ
¡Û ÀûÀÀÁõ
- ºÎ½º·³, ¿ËÁ¾, ¿¬Á¶Á÷¿°, ³ó°¡Áø, ³óÇÇÁõ, ´Üµ¶
- Æíµµ¿°, ÀÎÈĵο°, ºÎºñµ¿¿°, ÁßÀÌ¿°, ¸²ÇÁÀý¿°
- Æó·Å, Æó³ó¾ç, ³óÈä, ±â°üÁö¿°
- ÆÐÇ÷Áõ, ¼¼±Õ¼º½É³»¸·¿°,
- ÀÓÁú, ½Å¿ì½Å¿°, ¹æ±¤¿°, ¿äµµ¿°
- ¹ßÄ¡ÈÄ °¨¿°, ¿Ü»ó ¹× ¼ö¼úÈÄ 2Â÷°¨¿°
- º¹¸·¿°, °£³ó¾ç, ¼¼±Õ¼ºÀÌÁú
- °ñ¼ö¿°, Àڱó»°¨¿°
- ¹æ¼±±ÕÁõ, źÀú, ÀåÆ¼Çª½º
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
(ÁÖ»çÁ¦)
1. ±ÙÀ°ÁÖ»ç
¡Û ¼ºÀÎ : ¾ÏÇǽǸ°À¸·Î¼ 1ȸ 250¢¦1000mg(¿ª°¡) 1ÀÏ 2¢¦4ȸ ±ÙÀ°ÁÖ»çÇÑ´Ù.
2. Á¤¸ÆÁÖ»ç
¡Û ¼ºÀÎ : ¾ÏÇǽǸ°À¸·Î¼ ÁßÁõ°¨¿°¿¡ 1ÀÏ 1¢¦2g(¿ª°¡)À» 5% Æ÷µµ´ç ÁÖ»ç¾× ¶Ç´Â »ý¸®½Ä¿°ÁÖ»ç¾× 20mL¿¡ ³ì¿© 1¢¦2ȸ ºÐÇÒ Á¤¸ÆÁÖ»çÇϰí, Á¡Àû Á¤¸ÆÁÖ»çÀÇ °æ¿ì¿¡´Â 1ÀÏ 1¢¦2g(¿ª°¡)À» ¿°·ù º¸¾× ¶Ç´Â 5% Æ÷µµ´ç ÁÖ»ç¾× 500mL¿¡ ³ì¿© 1¢¦2ȸ ºÐÇÒ ÁÖ»çÇÑ´Ù.
ÆÐÇ÷Áõ, ¼¼±Õ¼º½É³»¸·¿°ÀÇ °æ¿ì¿¡´Â º¸Åë ¿ë·®º¸´Ù ´ë·®À» »ç¿ëÇÑ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ±Ý±â |
1) ÀÌ ¾à¿¡ ÀÇÇÏ¿© ¼ïÀÇ º´·ÂÀÌ Àִ ȯÀÚ
2) ÀÌ ¾à ¶Ç´Â Æä´Ï½Ç¸°À̳ª ¼¼ÆÈ·Î½ºÆ÷¸°°è Ç×»ý¹°Áú¿¡ °ú¹Î¹ÝÀÀ ¶Ç´Â ±× º´·ÂÀÌ Àִ ȯÀÚ
3) Àü¿°´ÜÇÙ±¸Áõ ȯÀÚ |
| ½ÅÁßÅõ¿© |
1) º»ÀÎ ¶Ç´Â ºÎ¸ð, ÇüÁ¦°¡ ±â°üÁöõ½Ä, ¹ßÁø, µÎµå·¯±â µîÀÇ ¾Ë·¹¸£±âÁõ»óÀ» ÀÏÀ¸Å°±â ½¬¿î üÁúÀΠȯÀÚ
2) ÁßÁõÀÇ ½ÅÀå¾Ö ȯÀÚ
3) °æ±¸¼·Ãë°¡ ºÒ·®ÇÑ È¯ÀÚ ¶Ç´Â ºñ°æ±¸¿µ¾ç ȯÀÚ, °í·ÉÀÚ, Àü½Å»óŰ¡ ³ª»Û ȯÀÚ(ºñŸ¹Î K °áÇÌÁõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇÑ´Ù.) |
| ÀÌ»ó¹ÝÀÀ |
1) ¼ï : µå¹°°Ô ¼ïÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇÏ°í ºÒÄè°¨, ±¸³»ÀÌ»ó°¨, õ¸í, ¾îÁö·¯¿ò, º¯ÀÇ, ÀÌ¸í µîÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
2) °ú¹Î¹ÝÀÀ : ¹ß¿, ¹ßÁø, µÎµå·¯±â µîÀÇ ¾Ë·¹¸£±â Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
3) ¼Òȱâ°è : µå¹°°Ô À§¸·¼º´ëÀå¿° µîÀÇ Ç÷º¯À» ¼ö¹ÝÇÏ´Â ÁßÁõÀÇ ´ëÀå¿°ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. º¹Åë, ºó¹øÇÑ ¼³»ç°¡ ³ªÅ¸³¯ °æ¿ì¿¡´Â Áï½Ã Åõ¿©¸¦ ÁßÁöÇÏ´Â µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù. ¶ÇÇÑ ¶§¶§·Î ¼³»ç, ±¸¿ª, ½Ä¿åºÎÁø µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) Ç÷¾×°è : µå¹°°Ô È£»ê±¸ Áõ°¡, ¹éÇ÷±¸ °¨¼Ò, ¹«°ú¸³±¸Áõ, Ç÷¼ÒÆÇ °¨¼Ò, ºóÇ÷, ¿ëÇ÷¼º ºóÇ÷ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) ÁßÃ߽Űæ°è : ½Å±â´É Àå¾Ö°¡ ÀÖÀ» ¶§ ¿ë·® Á¶ÀýÀ» ÇÏÁö ¾Ê¾ÒÀ» °æ¿ì, ÀνÄÀå¾Ö, ÇൿÀå¾Ö, °æ·Ã µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
6) ÇǺΠ: µå¹°°Ô ½ºÆ¼ºì½º-Á¸½¼ÁõÈıº, µ¶¼ºÇ¥ÇDZ«»ç¿ëÇØ°¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
7) °£Àå : µå¹°°Ô AST, ALT, ALPÀÇ »ó½Â, ´ãÁó ¿ïü¼º Ȳ´ÞÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
8) ½ÅÀå : µå¹°°Ô ±Þ¼º ½ÅºÎÀüµîÀÇ ÁßÁõÀÇ ½ÅÀå¾Ö°¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î Á¤±âÀûÀ¸·Î °Ë»ç¸¦ ÇÏ´Â µî ÃæºÐÈ÷ °üÂûÇÏ¿© ÀÌ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
9) ±Õ±³´ëÁõ : µå¹°°Ô ±Õ±³´ë¿¡ ÀÇÇÏ¿© ±¸³»¿°, ´ëÀå¿°ÀÌ Äµð´Ù ¶Ç´Â ºñ°¨¼ö¼º Ŭ·¹ºê½Ã¿¤¶ó µî¿¡ ÀÇÇØ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÏ´Â µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
10) ºñŸ¹Î °áÇÌÁõ : µå¹°°Ô ºñŸ¹Î K °áÇÌÁõ»ó(ÀúÇÁ·ÎÆ®·ÒºóÇ÷Áõ, ÃâÇ÷°æÇâµî), ºñŸ¹Î B±º °áÇÌÁõ»ó(¼³¿°, ±¸³»¿°, ½Ä¿åºÎÁø, ½Å°æ¿° µî)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
11) ±âŸ : ¾ß¸®½ÃÇ츤½ºÇÏÀÌ¸Ó ¹ÝÀÀ(¸Åµ¶ ȯÀÚ)ÀÌ ÀϾ ¼ö ÀÖ´Ù.
12) ³» ½ÃÆÇ ÈÄ ¼öÁýµÈ Áß´ëÇÑ ÀÌ»ó»ç·Ê ºÐ¼®¡¤Æò°¡ °á°ú È®ÀÎµÈ ÀÌ»ó»ç·Ê´Â ´ÙÀ½°ú °°´Ù. ´Ù¸¸, ÀÌ·Î½á °ð ÇØ´ç¼ººÐ°ú ´ÙÀ½ÀÇ ÀÌ»ó»ç·Ê °£¿¡ Àΰú°ü°è°¡ ÀÔÁõµÈ °ÍÀ» ÀǹÌÇÏ´Â °ÍÀº ¾Æ´Ï´Ù.
• ¸é¿ª°è : ¾Æ³ªÇʶô½Ã½º¹ÝÀÀ
|
| »óÈ£ÀÛ¿ë |
1) ¾ÏÇǽǸ°Àº °æ±¸ ÇÇÀÓ¾à°ú º´¿ëÅõ¿© ½Ã ÇÇÀÓÀÇ È¿°ú°¡ °¨¼ÒµÉ ¼ö ÀÖÀ¸¹Ç·Î ´Ù¸¥ ÇÇÀÓ¹ýÀ» Ãß°¡·Î »ç¿ëÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
2) ¾Ë·ÎǪ¸®³îÀº ¾ÏÇǽǸ°À¸·Î ÀÎÇÑ ÇǺιÝÀÀÀ» Áõ°¡½ÃŲ´Ù.
3) Á¤±Õ¼º Ç×»ý¹°Áú(Ŭ·Î¶÷Æä´ÏÄÝ, ¿¡¸®½º·Î¸¶À̽Å, Åׯ®¶ó»çÀÌŬ¸° µî)°ú º´¿ëÅõ¿© ½Ã ÀÌ ¾àÀÇ »ì±ÕÀÛ¿ëÀ» °¨¼Ò½Ãų ¼ö ÀÖ´Ù.
4) ÇÁ·Îº£³×½Ãµå¿Í º´¿ëÅõ¿© ½Ã ÀÌ ¾àÀÇ ¼¼´¢°ü ¹è¼³ ¼Óµµ°¡ °¨¼ÒµÇ¾î Ç÷Á߳󵵸¦ Áö¼Ó ½Ãų ¼ö ÀÖ´Ù.
5) º£Å¸ Â÷´ÜÁ¦¿Í º´¿ëÅõ¿© ½Ã ´ë»ç¼Óµµ°¡ ÀúÇ쵃 ¼ö ÀÖ´Ù. |
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Ampicillin¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Ampicillin¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Ampicillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Ampicillin interferes with an autolysin inhibitor.
|
| Pharmacology |
Ampicillin¿¡ ´ëÇÑ Pharmacology Á¤º¸ Ampicillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Ampicillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Ampicillin results from the inhibition of cell wall synthesis and is mediated through Ampicillin binding to penicillin binding proteins (PBPs). Ampicillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.
|
| Metabolism |
Ampicillin¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
|
| Protein Binding |
Ampicillin¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Half-life |
Ampicillin¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Ampicillin¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
Ampicillin sodiumÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- »ýü³»ÀÌ¿ë·ü : °æ±¸ : 50%
- ºÐÆ÷ : ´ãÁ󳻿¡ ºÐÆ÷, ¿°Áõ¼º ³ú¸·¿¡¼¸¸ ³úô¼ö¾×À¸·Î Àß Åõ°úµÈ´Ù (ÀϹÝÀûÀ¸·Î MICs ÀÌ»ó).
- ³úô¼ö¾× ´ë Ç÷¾×ÀÇ ³óµµºñ(%)
- Á¤»ó ³ú¸· : 0
- ¿°Áõ¼º ³ú¸· : 5-10
- ´Ü¹é°áÇÕ : 15-25%
- ¹Ý°¨±â :
- ½Å»ý¾Æ :
2-7ÀÏ : 4½Ã°£
8-14ÀÏ : 2.8½Ã°£
15-30ÀÏ : 1.7½Ã°£
- ¼Ò¾Æ ¹× ¼ºÀÎ : 1-1.8 ½Ã°£
- ¹«´¢Áõ/¸»±â ½ÅÁúȯ : 7-20 ½Ã°£
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : °æ±¸ : 1-2 ½Ã°£ À̳»
- ¼Ò½Ç : 24½Ã°£ À̳»¿¡ 90%±îÁö ¹Ìº¯Èü·Î ½Å¹è¼³µÈ´Ù.
|
| Biotransformation |
Ampicillin¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Ampicillin¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Ampicillin¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Methotrexate The penicillin increases the effect and toxicity of methotrexateAnisindione The IV penicillin increases the anticoagulant effectAtenolol Ampicillin decreases bioavailability of atenololDemeclocycline Possible antagonism of actionDicumarol The IV penicillin increases the anticoagulant effectDoxycycline Possible antagonism of actionEthinyl Estradiol This anti-infectious agent could decrease the effect of the oral contraceptiveMethacycline Possible antagonism of actionMinocycline Possible antagonism of actionAcenocoumarol The IV penicillin increases the anticoagulant effectOxytetracycline Possible antagonism of actionRolitetracycline Possible antagonism of actionTetracycline Possible antagonism of actionWarfarin The IV penicillin increases the anticoagulant effectMestranol This anti-infectious agent could decrease the effect of the oral contraceptive
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Ampicillin¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take on an empty stomach.
|
| Drug Target |
[Drug Target]
|
| Description |
Ampicillin¿¡ ´ëÇÑ Description Á¤º¸ Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic. [PubChem]
|
| Drug Category |
Ampicillin¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Bacterial AgentsPenicillins
|
| Smiles String Canonical |
Ampicillin¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1(C)SC2C(NC(=O)C(N)C3=CC=CC=C3)C(=O)N2C1C(O)=O
|
| Smiles String Isomeric |
Ampicillin¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
|
| InChI Identifier |
Ampicillin¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1/f/h18,22H
|
| Chemical IUPAC Name |
Ampicillin¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-08-19
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|